Navalign, LLC Allogene Therapeutics, Inc. Transaction History
Navalign, LLC
- $337 Million
- Q3 2024
A detailed history of Navalign, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Navalign, LLC holds 75,365 shares of ALLO stock, worth $166,556. This represents 0.06% of its overall portfolio holdings.
Number of Shares
75,365
Previous 75,365
-0.0%
Holding current value
$166,556
Previous $175,000
20.57%
% of portfolio
0.06%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding ALLO
# of Institutions
162Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$41.4 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$36.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$18.4 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$15.5 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$15.2 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $318M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...